The safety of biologic therapies in RA-associated interstitial lung disease.
about
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewThe role of biologics in treatment of connective tissue disease-associated interstitial lung diseaseSuccessful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case reportIncidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.Adverse reactions to biologic agents and their medical management.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease.Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis.Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab.Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
P2860
Q26775753-30A99C9C-E0EF-4C22-90AB-D92CB75D2491Q28082021-A8A0102E-6C85-4BE9-90B2-F40B06AB60A4Q35819534-E9168D0C-27B5-435E-809A-7E8257667EE2Q36270376-1838E2B1-5D30-48B3-ABD9-CF510E0B6205Q38238948-0212F8FD-DEED-4385-9039-F8F829196CA9Q38642378-E7B645B1-2EC5-493A-85B3-8CB33257BB21Q38819214-A3066D8E-1C57-4070-8382-1CE3D1547ED3Q39100810-37AD5D9A-2628-43F8-8392-3B6C3DAE7791Q39570333-9D4DA48C-6A71-4699-863E-C05C523955EFQ41687188-BF1FFBAA-17D9-4855-A241-41FADA61DB8BQ45903141-813CF3AC-7A8A-4B7C-B5C5-DA2C3E186D4DQ48097243-9DDE143B-AAF7-496E-BF94-7A7BAEA77D23Q52983676-4BE82252-0F35-4DF8-8DA6-A9ABD8F5778B
P2860
The safety of biologic therapies in RA-associated interstitial lung disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The safety of biologic therapies in RA-associated interstitial lung disease.
@en
type
label
The safety of biologic therapies in RA-associated interstitial lung disease.
@en
prefLabel
The safety of biologic therapies in RA-associated interstitial lung disease.
@en
P2860
P356
P1476
The safety of biologic therapies in RA-associated interstitial lung disease.
@en
P2093
Eric L Matteson
Nik Hirani
P2860
P2888
P304
P356
10.1038/NRRHEUM.2013.197
P407
P577
2013-12-24T00:00:00Z
P5875
P6179
1010146076